Health

STAT+: Launch prices for new medicines dipped slightly last year but remain high, analysis finds

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 20/10/2026, 13:51:25 UTC.

Briefings

A 2026 analysis by the Institute for Clinical and Economic Review and West Health reveals that the median net price for 202 newly launched medicines rose 35% to $257,000 in 2025, despite a 24% increase in list prices. Approximately 25% of these drugs had annual net prices exceeding $500,000, with 34% priced between $200,000 and $500,000. The divergence between rising list prices and net prices suggests varying manufacturer discounts across drug types, though specific reasons remain unanalyzed.

Key points

• The median net price for 202 newly launched medicines increased by 35% to $257,000 in 2025 compared to $190,000 in 2022.
• About 25% of drugs launched in 2025 had annual net prices exceeding $500,000, while 34% were priced between $200,000 and $500,000.

Context

This analysis by the Institute for Clinical and Economic Review and West Health examines prescription drug pricing trends amid ongoing concerns over high costs, highlighting that median net prices for new medicines rose significantly in 2025 despite modest increases in list prices.

Limitations

The analysis covers only 202 newly launched medicines and does not analyze specific reasons for the divergence between list and net prices. Data is limited to 2025 and 2022 comparisons, and the study relies on estimates from two nonprofit organizations rather than primary clinical trial data.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 20/10/2026, 14:40:19 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeif4cjuznnkwc5555u6obfpe2jtj5tzfh4wmywy7cl3zlwcmwgcdzu